Last updated: February 15, 2026
Drug Overview
NDC 63323-0044 corresponds to Inebilizumab, marketed as Uplizna. It is a monoclonal antibody used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), specifically targeting aquaporin-4 antibody-positive cases.
Current Market Landscape
- Indication: NMOSD, an autoimmune disorder causing severe neurological attacks.
- Approved Use: Uplizna received FDA approval in June 2020.
- Market Size: Estimated prevalence of NMOSD in the U.S. is approximately 4,000 to 6,000 patients, with about 70% being aquaporin-4 antibody-positive. The global prevalence is similarly low.
- Competitors: Eculizumab (Soliris), Satralizumab (Ensprygo), Rituximab (off-label). Eculizumab, marketed by Alexion, remains a primary competitor with estimated annual sales of ~$575 million globally.
Market Dynamics
- The market for NMOSD treatments is constrained by disease rarity but is growing due to increased diagnosis and off-label use of similar biologics.
- Uplizna's approval positioned it as a targeted therapy with a novel mechanism. It offers a potential differentiation from broad immunosuppressants like rituximab.
- The treatment landscape is competitive, with off-label rituximab use prevalent because of lower costs.
Pricing Analysis
- Uplizna's list price: Approximately $150,000 to $180,000 per year for a typical course.
- Prices vary by region, with U.S. prices higher than European or other markets due to healthcare pricing models.
- Reimbursement scenario: Insurance coverage includes Medicare, Medicaid, and private insurers, with prior authorization typically required.
Price Projections (Next 5 Years)
| Year |
Estimated Price Range |
Key Factors |
Source/Reference |
| 2023 |
$150,000 - $180,000 |
Current list price |
U.S. pricing reports[1] |
| 2024 |
$150,000 - $185,000 |
Slight inflation/price adjustments |
Industry pricing trends[2] |
| 2025 |
$155,000 - $190,000 |
Patent protection, inflation |
Patent expiry considerations[3] |
| 2026 |
$160,000 - $195,000 |
Competition impacts, biosimilar entry |
Biosimilar landscape developments |
| 2027 |
$165,000 - $200,000 |
Patent expirations, market growth |
Historical biosimilar entry patterns[4] |
Drivers of Price Stability and Increase
- Limited competition due to the rarity of NMOSD.
- High development and manufacturing costs associated with monoclonal antibody production.
- Increasing demand from expanded indications and off-label usage.
Potential Price Reduction Factors
- Biosimilar competition delivery could generate discounts after patent expiry (~2028-2030).
- Healthcare policy reforms aimed at cost containment.
- Greater uptake of more cost-effective biosimilars or generics (if biosimilar pathways are approved).
Regulatory and Patent Timeline
- The U.S. patent protecting Inebilizumab is expected to expire around 2028-2030.
- Biosimilar entrants projected shortly after patent expiry, potentially reducing prices by 30-50%.
External Market Risks and Opportunities
- Regulatory delays or approvals of biosimilars could extend Uplizna’s market dominance.
- Expanded indications or new formulations would support sustained pricing.
- Price bargaining by payers may limit revenue growth.
Key Takeaways
- Uplizna (NDC 63323-0044) addresses a niche but increasing market for NMOSD.
- Current annual list price: $150,000 to $180,000.
- Price projections suggest slight increases annually due to inflation and market factors.
- Significant reductions expected post-patent expiry (~2028-2030) with biosimilar entry.
- Market growth depends on increased diagnosis, payer acceptance, and potential expanded indications.
FAQs
1. What is the primary competitor for Uplizna?
Eculizumab (Soliris) by Alexion, with annual sales of approximately $575 million.
2. When is biosimilar entry expected?
Likely post-2028, following patent expiry, with potential price reductions of up to 50%.
3. How does the rarity of NMOSD influence pricing?
Limited patient population sustains high per-unit prices due to market exclusivity and high R&D costs.
4. Are there off-label treatments impacting Uplizna’s market?
Yes, rituximab is used off-label, exerting downward pressure on prices and market share.
5. What factors could influence Uplizna’s future price?
Patent expiry, biosimilar development, healthcare policy reforms, and clinical trial results for new indications.
References
[1] Pricing reports from healthcare industry sources, 2023;
[2] Industry trend analyses, Scrip Intelligence, 2022;
[3] Patent expiration timelines, USPTO, 2023;
[4] Biosimilar market entry data, FDA biosimilar approval reports, 2022.
